2. Conference Papers28
-
1
Conference
A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial
김한조
2024
-
2
Conference
Nationwide real-world practice pattern and clinical data of palbociclib in patients with HR(+), HER2(-) metastatic breast cancer (KCSG BR21-15)
김한조
2024
-
3
Conference
Hidden advertisements included in cancer information posts: Insights from social listening
이상철
2024
-
4
Conference
Comprehensive analysis of mutation and expression based pathways in head and neck squamous cell carcinoma
이상철
2018
-
5
Conference
Attenuated FOLFIRINOX (5-FU/LV, irinotecan and oxaliplatin) as second-line chemotherapy for the Koreans (Asian population) with gemcitabine-resistant or –refractory advanced pancreatic cancer
이상철
;
이규택
;
배상병
;
et al
2016
-
6
Conference
Modified FOLFIRINOX versus S-1 as second-line chemotherapy in patients with gemcitabine-failed metastatic pancreatic cancer: A randomized phase III trial (MPACA-3)
이상철
2021
-
7
Conference
Multicenter phase II study of docetaxel and oxaliplatin combination in patients with locally advanced or metastatic biliary tract cancer
이규택
;
배상병
;
김한조
2014
-
8
Conference
Phase II study of gemcitabine and vinorebline in patients with persistent or recurrent platinum-resistant ovarian or primary peritoneal cancer: A study of the Korean Cancer Study Group
이상철
2014
-
9
Conference
A phase II trial of weekly docetaxel for second-line treatment of urothelial carcinoma
이상철
2013
-
10
Conference
Pilot trial of epidermal growth factor (EGF) ointment for the patients with epidermal growth factor receptor (EGFR) inhibitor related skin side effects
이상철
2018
-
11
Conference
Antiemetic effectiveness of palonosetron and first-generation serotonin inhibitors for high emetic risk chemotherapy in the post-aprepitant era
김한조
;
이상철
;
배상병
;
et al
2012
-
12
Conference
A randomized phase II clinical trial of gemcitabine, oxaliplatin, erlotinib combination chemotherapy versus gemcitabine and erlotinib in previously untreated patients with locally advanced or metastatic pancreatic cancer
김한조
;
이상철
;
배상병
;
et al
2018
-
13
Conference
Simvastatin plus capecitabine-cisplatin (XP) versus placebo plus capecitabine-cisplatin (XP) in patients with previously untreated advanced gastric cancer: A double-blind randomized phase 3 study
이상철
2014
-
14
Conference
A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10, NCT02592746)
김한조
2019
-
15
Conference
Division of elderly patients in colorectal cancer: Korean national health insurance big data analysis
이상철
;
배상병
2017
-
16
Conference
Effect of dose escalation with single opioid, fentanyl matrix, for current cancer pain management: Multicenter, prospective, observational study
이규택
2012
-
17
Conference
PEARLY: A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with early triple-negative breast cancer
김한조
2017
-
18
Conference
A phase II study of gemcitabine, oxaliplatin, and erlotinib (GEMOX-T) combination chemotherapy in previously untreated patients with locally advanced unresectable or metastatic pancreatic cancer
김한조
;
이상철
;
배상병
;
et al
2014
-
19
Conference
Prognostic factor analysis of second-line chemotherapy in advanced biliary tract cancer
이상철
;
김한조
;
배상병
;
et al
2012
-
20
Conference
Prospective multicenter study evaluating adrenal suppression after dexamethasone therapy as an antiemetic in cancer patients: a KSWOG (Korean South West Oncology Group) study
이규택
;
배상병
;
김한조
2015